Otherwise, simply enhancing adrenergic signaling without correcting RyR2 dysfunction (like β-AR agonists) may exacerbate RyR2 dysfunction and Ca2+ leak, increasing the arrhythmia risk and sudden cardiac death in HF. This evidence concerns the gene ADRB2 and cardiac arrhythmia.